The Bone Zone Trial aims to prevent bone loss in critically ill men and women following admission to intensive care for greater than two days. This is an important study because critical illness may adversely affect the well-being of survivors through increased bone turnover and accelerated bone loss in the following years. Older women who survive critical illness have a significantly higher fragility fracture rate compared to community age-matched controls. Men also experience an increased loss of bone mineral density (BMD) following critical illness in the year after having significantly greater decreases in BMD compared to age adjusted population controls.
The Bone Zone Trial is looking at comparing the effect of subcutaneous denosumab or intravenous zoledronic acid to placebo on change in BMD over one year in women aged 50 years or older and men aged 70 years or older.
South West Health (SWH) is Victoria’s largest sub-regional health service provider, and has partnered with Barwon Health (BH) to run the trial to benefit local community members. Participants have their initial treatment at BH (Geelong) following their intensive care stay, but if they live in the South West region will have the option for follow-up trial treatments closer to home.
If you could like more information please email clinicaltrials@swh.net.au
